Aprea Therapeutics Confirms Partial Response for APR-1051
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy APRE?
Aprea Therapeutics announced the confirmation of a partial response, or PR, in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor. The confirmed PR was observed in a patient with PPP2R1A-mutated endometrial cancer who is currently being treated at the 220 mg once daily dose level. Aprea announced on February 18 that, at their first imaging assessment, this patient achieved a 50% reduction in target lesion size as well as a reduction in CA-125 levels. This response was subsequently confirmed at the second image assessment, with an additional 9.5% reduction in target lesion size, and a reduction in CA-125 to 40.2U/ml. ACESOT-1051 is a biomarker focused Phase 1 trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors harboring cancer-associated genetic alterations. A total of 24 patients have been treated to date, at doses ranging from 10 mg to 220 mg once daily. Two patients have achieved partial responses, both with endometrial cancers harboring PPP2R1A mutations. One of these responses has been confirmed, as described above. Both patients remain on treatment. Five other patients in ACESOT-1051 have achieved a best overall response of stable disease, including patients with HPV+ head and neck squamous cell carcinoma, colorectal and endometrial cancers with relevant genomic alternations. APR-1051 has been generally safe and well tolerated with the most common adverse events reported as Grade 1 or 2, primarily consisting of nausea and fatigue. Dose escalation is ongoing, with plans to advance to Dose Level 9 in the second quarter of 2026. In parallel, the company plans to enroll additional patients as specified in the protocol based on the understanding that their tumor types or specific mutations gives them an increased probability of responding to this class of potential therapeutics. This includes patients with uterine serous carcinoma, colorectal and HPV+ tumors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APRE
Wall Street analysts forecast APRE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.699
Low
4.00
Averages
5.33
High
7.00
Current: 0.699
Low
4.00
Averages
5.33
High
7.00
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
- Successful Financing: Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds allocated for general corporate purposes and R&D expenses, thereby enhancing financial flexibility to support its clinical projects.
- Clinical Trial Progress: The company's lead candidate APR-1051 is undergoing a Phase 1 trial for advanced solid tumors, showing promising clinical activity, with further updates expected in Q2 2026, which could drive stock price appreciation.
- Analyst Rating Maintained: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating for Aprea with a 12-month price target of $7, reflecting market confidence in its product potential and likely attracting more investor interest.
- Cash Flow Status: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and with the recent financing, projected a cash runway through Q1 2027, providing a safeguard for the company's future development.
See More
Aprea Therapeutics Closes $30 Million Financing
- Significant Financing: Aprea Therapeutics has successfully closed an oversubscribed private placement financing, raising approximately $30 million, which will provide robust funding for the company's research and operational needs, expected to accelerate the development of targeted therapies for biomarker-defined cancers.
- Investor Confidence: The financing was led by top-tier biotech investor Soleus Capital, with participation from new investors such as Vestal Point Capital and Squadron Capital Management, reflecting strong market confidence in the potential of APR-1051 to impact cancer treatment.
- Clinical Trial Expansion: Aprea plans to enroll at least 50 patients with uterine serous carcinoma and platinum-resistant ovarian cancer to evaluate the efficacy of APR-1051, a strategy that will help clarify the clinical development path and accelerate insight generation in biomarker-defined patient populations.
- Future Development Outlook: The company intends to exercise the newly issued warrants before 2029, further strengthening its capital structure to support innovation and competitiveness in the cancer treatment market.
See More
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
- Clinical Trial Progress: Aprea Therapeutics reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during its ongoing Phase 1 ACESOT-1051 trial, with a 50% reduction in tumor size at the first imaging assessment and an additional 9.5% reduction at the second assessment, indicating the drug's potential efficacy.
- Enrollment Expansion Plans: The company plans to enroll at least 50 patients with uterine serous carcinoma and other high-need patient groups beyond the existing biomarker-enriched cohorts, addressing significant unmet medical needs, with dose escalation expected to complete by the second quarter of 2027.
- Financing Details: Aprea announced an oversubscribed $30 million private placement led by Soleus Capital, with proceeds intended for general corporate purposes and R&D activities, which is expected to extend the company's cash runway into the first quarter of 2028.
- Stock Performance: APRE shares have traded between $0.54 and $2.30 over the past year, closing at $0.68, down 2.43% on the last trading day, but showing an 8.35% increase in pre-market trading, reflecting positive market sentiment regarding its financing and clinical advancements.
See More
Aprea Therapeutics Reports Q4 2025 Financial Results
- Financial Highlights: Aprea Therapeutics reported a Q4 2025 GAAP EPS of -$0.32, beating expectations by $0.07, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Comparison: The company generated revenue of $3,340 this quarter, a significant drop from $210,000 in the same period last year, reflecting a notable decline in product sales or service demand, which may impact future cash flow.
- Cash Position: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, down from $22.8 million in 2024, indicating pressure on the company's financial management and raising concerns about its future financing capabilities.
- Financing Strategy: Aprea plans to utilize proceeds from a $5.6 million private placement completed in January 2026 to support operations, with expectations that these funds will be sufficient to cover operating and capital expenditure needs into Q1 2027, demonstrating strategic planning for its cash flow.
See More
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
- Significant Tumor Reduction: Aprea Therapeutics reported a 50% tumor shrinkage in a patient from its early-stage trial of APR-1051, alongside a notable decline in the tumor biomarker CA-125, indicating the drug's potential therapeutic impact and strengthening the company's market outlook.
- Mild Side Effects: The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, suggesting good tolerability of APR-1051, which provides positive safety data for future clinical trials.
- Follow-Up Assessment Plans: The company is eyeing confirmation of the partial responses observed in both patients through subsequent imaging assessments, with further updates expected in Q2 2026, which could positively influence investor confidence.
- Positive Market Reaction: Following the announcement, Aprea's shares surged 15%, with all analysts covering the stock rating it as 'Buy' or higher, and a 12-month average price target of $5.33, representing a potential upside of approximately 788%, reflecting optimistic market sentiment regarding its future performance.
See More
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
- Successful Financing: Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds allocated for general corporate purposes and R&D expenses, thereby enhancing financial flexibility to support its clinical projects.
- Clinical Trial Progress: The company's lead candidate APR-1051 is undergoing a Phase 1 trial for advanced solid tumors, showing promising clinical activity, with further updates expected in Q2 2026, which could drive stock price appreciation.
- Analyst Rating Maintained: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating for Aprea with a 12-month price target of $7, reflecting market confidence in its product potential and likely attracting more investor interest.
- Cash Flow Status: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and with the recent financing, projected a cash runway through Q1 2027, providing a safeguard for the company's future development.
See More
Aprea Therapeutics Closes $30 Million Financing
- Significant Financing: Aprea Therapeutics has successfully closed an oversubscribed private placement financing, raising approximately $30 million, which will provide robust funding for the company's research and operational needs, expected to accelerate the development of targeted therapies for biomarker-defined cancers.
- Investor Confidence: The financing was led by top-tier biotech investor Soleus Capital, with participation from new investors such as Vestal Point Capital and Squadron Capital Management, reflecting strong market confidence in the potential of APR-1051 to impact cancer treatment.
- Clinical Trial Expansion: Aprea plans to enroll at least 50 patients with uterine serous carcinoma and platinum-resistant ovarian cancer to evaluate the efficacy of APR-1051, a strategy that will help clarify the clinical development path and accelerate insight generation in biomarker-defined patient populations.
- Future Development Outlook: The company intends to exercise the newly issued warrants before 2029, further strengthening its capital structure to support innovation and competitiveness in the cancer treatment market.
See More
Wedbush Reiterates Outperform Rating for Aprea Therapeutics
- Successful Financing: Aprea Therapeutics announced the completion of an oversubscribed private placement financing totaling approximately $30 million, which will provide crucial funding for its clinical trials and product development, enhancing the company's competitiveness in the biopharmaceutical sector.
- Clinical Trial Progress: The company's lead product candidate, APR-1051, is undergoing a Phase 1 clinical trial for patients with advanced solid tumors harboring cancer-associated genetic alterations, with preliminary data showing positive clinical activity, laying the groundwork for future market introduction.
- Dose Escalation Study: The dose-escalation study for APR-1051 is ongoing, with plans to advance to the 300 mg once-daily dose cohort in the second quarter of 2026, which will include patients with uterine serous carcinoma, colorectal cancer, and HPV+ tumors, demonstrating the company's continued commitment to clinical research.
- Market Performance: Aprea Therapeutics' stock has traded between $0.54 and $2.30 over the past year, currently priced at $0.78, reflecting a 5.98% increase, indicating positive market sentiment regarding its clinical advancements.
See More
Aprea Therapeutics Secures $30 Million Financing for APR-1051 Development
- Clinical Trial Progress: Aprea Therapeutics reported a confirmed partial response in a patient with PPP2R1A-mutated endometrial cancer during its ongoing Phase 1 ACESOT-1051 trial, with a 50% reduction in tumor size at the first imaging assessment and an additional 9.5% reduction at the second assessment, indicating the drug's potential efficacy.
- Enrollment Expansion Plans: The company plans to enroll at least 50 patients with uterine serous carcinoma and other high-need patient groups beyond the existing biomarker-enriched cohorts, addressing significant unmet medical needs, with dose escalation expected to complete by the second quarter of 2027.
- Financing Details: Aprea announced an oversubscribed $30 million private placement led by Soleus Capital, with proceeds intended for general corporate purposes and R&D activities, which is expected to extend the company's cash runway into the first quarter of 2028.
- Stock Performance: APRE shares have traded between $0.54 and $2.30 over the past year, closing at $0.68, down 2.43% on the last trading day, but showing an 8.35% increase in pre-market trading, reflecting positive market sentiment regarding its financing and clinical advancements.
See More
Aprea Therapeutics Reports Q4 2025 Financial Results
- Financial Highlights: Aprea Therapeutics reported a Q4 2025 GAAP EPS of -$0.32, beating expectations by $0.07, indicating a slight improvement in financial performance despite remaining in a loss position.
- Revenue Comparison: The company generated revenue of $3,340 this quarter, a significant drop from $210,000 in the same period last year, reflecting a notable decline in product sales or service demand, which may impact future cash flow.
- Cash Position: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, down from $22.8 million in 2024, indicating pressure on the company's financial management and raising concerns about its future financing capabilities.
- Financing Strategy: Aprea plans to utilize proceeds from a $5.6 million private placement completed in January 2026 to support operations, with expectations that these funds will be sufficient to cover operating and capital expenditure needs into Q1 2027, demonstrating strategic planning for its cash flow.
See More
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
- Significant Tumor Reduction: Aprea Therapeutics reported a 50% tumor shrinkage in a patient from its early-stage trial of APR-1051, alongside a notable decline in the tumor biomarker CA-125, indicating the drug's potential therapeutic impact and strengthening the company's market outlook.
- Mild Side Effects: The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, suggesting good tolerability of APR-1051, which provides positive safety data for future clinical trials.
- Follow-Up Assessment Plans: The company is eyeing confirmation of the partial responses observed in both patients through subsequent imaging assessments, with further updates expected in Q2 2026, which could positively influence investor confidence.
- Positive Market Reaction: Following the announcement, Aprea's shares surged 15%, with all analysts covering the stock rating it as 'Buy' or higher, and a 12-month average price target of $5.33, representing a potential upside of approximately 788%, reflecting optimistic market sentiment regarding its future performance.
See More
